Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLGW) Income from Continuing Operations (2016 - 2017)

Bone Biologics (BBLGW) has disclosed Income from Continuing Operations for 2 consecutive years, with 2769609.0 as the latest value for Q4 2017.

  • Quarterly Income from Continuing Operations rose 41.05% to 2769609.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was 7051573.0 through Dec 2017, up 72.75% year-over-year, with the annual reading at 3112958.0 for FY2025, 25.23% up from the prior year.
  • Income from Continuing Operations for Q4 2017 was 2769609.0 at Bone Biologics, down from 2375739.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 1016301.0 in Q2 2017, with the low at 12263789.0 in Q1 2016.